1. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction
- Author
-
Clotilde Roy, Sibille Lejeune, Alisson Slimani, Christophe deMeester, Sylvie A. Ahn AS, Michel F. Rousseau, Amzulescu Mihaela, Audrey Ginion, Benjamin Ferracin, Agnès Pasquet, David Vancraeynest, Christophe Beauloye, Jean‐Louis Vanoverschelde, Sandrine Horman, Damien Gruson, Bernhard L. Gerber, and Anne‐Catherine Pouleur
- Subjects
FGF‐23 ,Biomarker ,Troponin ,Mortality ,NT‐proBNP ,Heart failure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Besides regulating calcium‐phosphate metabolism, fibroblast growth factor 23 (FGF‐23) has been associated with incident heart failure (HF) and left ventricular hypertrophy. However, data about FGF‐23 in HF and preserved ejection fraction (HFpEF) remain limited. The aim of this study was to assess the association between FGF‐23 levels, clinical and imaging characteristics, particularly diffuse myocardial fibrosis, and prognosis in HFpEF patients. Methods and results We prospectively included 143 consecutive HFpEF patients (78 ± 8 years, 61% female patients) and 31 controls of similar age and gender (75 ± 6 years, 61% female patients). All subjects underwent a complete two‐dimensional echocardiography and cardiac magnetic resonance with extracellular volume (ECV) assessment by T1 mapping. FGF‐23 was measured at baseline. Among the patients, differences in clinical and imaging characteristics across tertiles of FGF‐23 levels were analysed with a trend test across the ordered groups. Patients were followed over time for a primary endpoint of all‐cause mortality and first HF hospitalization and a secondary endpoint of all‐cause mortality. Median FGF‐23 was significantly higher in HFpEF patients compared with controls of similar age and gender (247 [115; 548] RU/mL vs. 61 [51; 68] RU/mL, P
- Published
- 2020
- Full Text
- View/download PDF